研究者業績

佐久間 康成

サクマ ヤスナル  (Yasunaru Sakuma)

基本情報

所属
自治医科大学 附属病院移植・再生医療センター 教授

通称等の別名
Yasunaru Sakuma
研究者番号
10296105
J-GLOBAL ID
202001003024187832
researchmap会員ID
R000014289

論文

 650
  • 山田 百合子, 田口 昌延, 谷口 理丈, 森嶋 計, 天野 雄介, 福嶋 敬宜, 遠藤 和洋, 笹沼 英紀, 佐久間 康成, 細谷 好則, 堀江 久永, 山口 博紀, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 84(増刊) S462-S462 2023年10月  
  • 藤沼 香栄, 田口 昌延, 下平 健太郎, 森嶋 計, 三木 厚, 兼田 裕司, 遠藤 和洋, 笹沼 英紀, 佐久間 康成, 細谷 好則, 堀江 久永, 山口 博紀, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 84(増刊) S515-S515 2023年10月  
  • 堀内 俊男, 眞田 幸弘, 高寺 樹一朗, 大豆生田 尚彦, 平田 雄大, 岡田 憲樹, 脇屋 太一, 大西 康晴, 三谷 忠宏, 熊谷 秀規, 佐久間 康成, 佐田 尚宏
    日本小児栄養消化器肝臓学会雑誌 37(Suppl.) 86-86 2023年10月  
  • Atsushi Miki, Yasunaru Sakuma, Jun Watanabe, Kazuhiro Endo, Hideki Sasanuma, Takumi Teratani, Alan Kawarai Lefor, Atsushi Shimizu, Joji Kitayama, Yoshikazu Yasuda, Naohiro Sata
    Scientific Reports 13(1) 2023年9月20日  
    Abstract It is important to assess the prognosis and intervene before and after surgery in patients with hepatocellular carcinoma. This study aims to elucidate the association of outcomes and residual liver function after hepatectomy. A total of 176 patients who underwent the initial resection for hepatocellular carcinoma between January 2011 and March 2021 at Jichi Medical University were included. Hepatic clearance of the remnant liver was measured using 99mTc-galactosyl serum albumin scintigraphy. The log-rank test was used to analyze survival using the Kaplan–Meier method. Hazard ratios (HR) and 95% confidence intervals (CI) for overall survival were calculated using Cox’s proportional hazard model. In multivariate analysis, microvascular invasion, intraoperative blood loss, and hepatic clearance of the remnant liver were independently associated with overall survival. Hepatic clearance of the remnant liver was independently associated with recurrence free survival. This is the first report to show that lower residual liver function is associated with shorter survival in patients with hepatocellular carcinoma undergoing hepatectomy. Preoperative determination of remnant liver function may allow assessment of prognosis in patients planned to undergo resection of hepatocellular carcinoma. Preservation of liver functional reserve may be crucial for improved long-term outcomes after hepatectomy.
  • Kiri Koshu, Kazuhiro Muramatsu, Tomomi Maru, Yoshie Kurokawa, Yoshitaka Mizobe, Hirokazu Yamagishi, Daisuke Matsubara, Koji Yokoyama, Eriko Jimbo, Hideki Kumagai, Yukihiro Sanada, Yasunaru Sakuma, Noriyoshi Fukushima, Aya Narita, Takanori Yamagata, Hitoshi Osaka
    Brain & development 45(9) 517-522 2023年7月8日  
    BACKGROUND: Niemann-Pick disease type C (NPC) is an autosomal recessive inherited and neurodegenerative disorder. Approximately 10% of NPC patients have acute liver failure and sometimes need liver transplantation (LT), and 7% reportedly develop inflammatory bowel disease (IBD). We report the case of a girl with NPC who had a re- accumulation of cholesterol in the transplanted liver and NPC-related IBD. CASE REPORT: The patient underwent living donor liver transplantation (LDLT) due to severe acute liver failure caused by an unknown etiology inherited from her father. At 1 year and 6 months (1Y6M), she developed neurological delay, catalepsy, and vertical supranuclear gaze palsy. The foam cells were found in her skin, and fibroblast Filipin staining was positive; hence, she was diagnosed with NPC. It was identified that her father had NPC heterozygous pathogenic variant. At 2 years, she had anal fissure, skin tag and diarrhea. She was diagnosed with NPC-related IBD, using a gastrointestinal endoscopy. Three years after LT, liver biopsy revealed foam cells and numerous fatty droplets. At 8 years, broken hepatocytes and substantial fibrosis were observed. She died from circulation failure due to hypoalbuminemia at 8Y2M. CONCLUSIONS: In NPC, load of cholesterol metabolism is suggested to persist even after LT. LDLT from NPC heterozygous variant donor was insufficient to metabolize cholesterol overload. In NPC patients, the possibility of cholesterol re-accumulation should be considered when LT is performed. NPC-related IBD should be considered when NPC patients have anorectal lesions or diarrhea.
  • 森嶋 計, 下平 健太郎, 青木 裕一, 田口 昌延, 遠藤 和洋, 笹沼 英紀, 佐久間 康成, 福嶋 敬宜, 佐田 尚宏
    膵臓 38(3) A464-A464 2023年7月  
  • 藤沼 香栄, 田口 昌延, 下平 健太郎, 青木 裕一, 目黒 由行, 森嶋 計, 三木 厚, 宮戸 秀世, 大澤 英之, 兼田 裕司, 遠藤 和洋, 小泉 大, 吉田 淳, 笹沼 英紀, 山口 博紀, 佐久間 康成, 北山 丈二, 佐田 尚宏
    膵臓 38(3) A392-A392 2023年7月  
  • 田口 昌延, 笹沼 英紀, 下平 健太郎, 青木 裕一, 目黒 由行, 森嶋 計, 三木 厚, 宮戸 秀世, 大澤 英之, 兼田 裕司, 遠藤 和洋, 小泉 大, 吉田 淳, 山口 博紀, 佐久間 康成, 北山 丈二, 佐田 尚宏
    膵臓 38(3) A405-A405 2023年7月  
  • 森嶋 計, 下平 健太郎, 青木 裕一, 田口 昌延, 遠藤 和洋, 笹沼 英紀, 佐久間 康成, 福嶋 敬宜, 佐田 尚宏
    膵臓 38(3) A464-A464 2023年7月  
  • 眞田 幸弘, 佐久間 康成, 大西 康晴, 脇屋 太一, 岡田 憲樹, 平田 雄大, 堀内 俊男, 片野 匠, 大豆生田 尚彦, 高寺 樹一朗, 関谷 菜津美, 吉田 幸世, 佐田 尚宏
    小児外科 55(6) 609-617 2023年6月  
  • 平田 雄大, 眞田 幸弘, 大西 康晴, 脇屋 太一, 岡田 憲樹, 堀内 俊男, 大豆生田 尚彦, 高寺 樹一朗, 佐久間 康成, 佐田 尚宏
    小児外科 55(6) 654-659 2023年6月  
  • 田口 昌延, 笹沼 英紀, 下平 健太郎, 森嶋 計, 三木 厚, 宮戸 秀世, 吉田 淳, 大澤 英之, 兼田 裕司, 遠藤 和洋, 小泉 大, 山口 博紀, 佐久間 康成, 北山 丈二, 佐田 尚宏
    日本胆膵病態・生理研究会プログラム・抄録集 40回 24-24 2023年6月  
  • 笹沼 英紀, 佐田 尚宏, 下平 健太郎, 青木 裕一, 田口 昌延, 森嶋 計, 三木 厚, 遠藤 和洋, 小泉 大, 吉田 淳, 佐久間 康成, 北山 丈二
    日本外科系連合学会誌 48(3) 289-289 2023年5月  
  • 笹沼 英紀, 伊澤 祥光, 佐久間 康成, 堀江 久永, 細谷 好則, 間藤 卓, 布宮 伸, 瓦井Lefor Alan, 北山 丈二, 佐田 尚宏
    日本腹部救急医学会雑誌 43(4) 707-713 2023年5月  
  • 太田 学, 堀江 久永, 宮原 悠三, 本間 祐子, 太白 健一, 佐田友 藍, 田原 真紀子, 井上 賢之, 鯉沼 広治, 山口 博紀, 佐久間 康成, 川平 洋, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 123回 PD-6 2023年4月  
  • 兼田 裕司, 木村 有希, 齋藤 晶, 小泉 大, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 123回 HFT-3 2023年4月  
  • 兼田 裕司, 木村 有希, 齋藤 晶, 小泉 大, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 123回 HFT-3 2023年4月  
  • 清水 敦, 野田 泰子, 佐久間 康成, 大西 康晴, 笹沼 英紀, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 123回 SF-4 2023年4月  
  • 大西 康晴, 佐久間 康成, 眞田 幸弘, 脇屋 太一, 岡田 憲樹, 平田 雄大, 堀内 俊男, 大豆生田 尚彦, 水田 耕一, 佐田 尚宏
    日本外科学会定期学術集会抄録集 123回 DP-6 2023年4月  
  • 眞田 幸弘, 佐久間 康成, 大西 康晴, 脇屋 太一, 岡田 憲樹, 平田 雄大, 堀内 俊男, 片野 匠, 大豆生田 尚彦, 佐田 尚宏
    日本外科学会定期学術集会抄録集 123回 DP-8 2023年4月  
  • Atsushi Miki, Yasunaru Sakuma, Jun Watanabe, Kazuhiro Endo, Hideki Sasanuma, Takumi Teratani, Alan Kawarai Lefor, Joji Kitayama, Naohiro Sata
    Current Oncology 30(2) 1860-1868 2023年2月2日  
    Background: The prognostic importance of osteopenia in patients with intrahepatic cholangiocarcinoma (ICC) undergoing hepatectomy is unclear. The aim of this study was to evaluate the impact of osteopenia on survival in patients with ICC. Methods: A total of 71 patients who underwent hepatectomy at Jichi Medical University between July 2008 and June 2022 were included in this study. Non-contrast computed tomography scan images at the eleventh thoracic vertebra were used to assess bone mineral density. The cutoff value was calculated using a threshold value of 160 Hounsfield units. Overall survival curves were made using the Kaplan–Meier method and the log-rank test was used to evaluate survival. The hazard ratio (HR) and 95% confidence interval (CI) for overall survival were calculated using Cox’s proportional hazard model. Results: In multivariable analysis, osteopenia (HR 3.66, 95%CI 1.16–14.1, p = 0.0258) and the platelet–lymphocyte ratio (HR 6.26, 95%CI 2.27–15.9, p = 0.0008) were significant independent factors associated with overall survival. There were no significant independent prognostic factors for recurrence-free survival. Conclusions: Preoperative osteopenia is significantly associated with postoperative survival in patients with ICC undergoing hepatectomy.
  • 田中 保平, 太田 学, 宮戸 秀世, 本間 祐子, 太白 健一, 佐田友 藍, 田原 真紀子, 鯉沼 広治, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本腹部救急医学会雑誌 43(2) 469-469 2023年2月  
  • 窪木 大悟, 太田 学, 金丸 理人, 倉科 憲太郎, 鯉沼 広治, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本腹部救急医学会雑誌 43(2) 566-566 2023年2月  
  • 平田 雄大, 眞田 幸弘, 大西 康晴, 脇屋 太一, 岡田 憲樹, 堀内 俊男, 大豆生田 尚彦, 佐久間 康成, 佐田 尚宏
    日本小児外科学会雑誌 59(1) 149-149 2023年2月  
  • 堀内 俊男, 眞田 幸弘, 大豆生田 尚彦, 平田 雄大, 岡田 憲樹, 脇屋 太一, 大西 康晴, 佐久間 康成
    日本小児外科学会雑誌 59(1) 150-150 2023年2月  
  • 眞田 幸弘, 大豆生田 尚彦, 片野 匠, 堀内 俊男, 平田 雄大, 岡田 憲樹, 脇屋 太一, 大西 康晴, 関谷 菜津美, 吉田 幸世, 佐久間 康成
    日本小児外科学会雑誌 59(1) 152-152 2023年2月  
  • 佐久間 康成, 平田 雄大, 岡田 憲樹, 眞田 幸弘, 大西 康晴, 佐田 尚宏
    手術 77(1) 45-51 2023年1月  
  • Takumi Teratani, Naoya Kasahara, Yasuhiro Fujimoto, Yasunaru Sakuma, Atsushi Miki, Masafumi Goto, Naohiro Sata, Joji Kitayama
    Islets 14(1) 69-81 2022年12月31日  
    The success of islet transplantation in both basic research and clinical settings has proven that cell therapy has the potential to cure diabetes. Islets intended for transplantation are inevitably subjected to damage from a number of sources, including ischemic injury during removal and delivery of the donor pancreas, enzymatic digestion during islet isolation, and reperfusion injury after transplantation in the recipient. Here, we found that protein factors secreted by porcine adipose-tissue mesenchymal stem cells (AT-MSCs) were capable of activating preserved porcine islets. A conditioned medium was prepared from the supernatant obtained by culturing porcine AT-MSCs for 2 days in serum-free medium. Islets were preserved at 4°C in University of Wisconsin solution during transportation and then incubated at 37°C in RPMI-1620 medium with fractions of various molecular weights prepared from the conditioned medium. After treatment with certain fractions of the AT-MSC secretions, the intracellular ATP levels of the activated islets had increased to over 160% of their initial values after 4 days of incubation. Our novel system may be able to restore the condition of isolated islets after transportation or preservation and may help to improve the long-term outcome of islet transplantation.Abbreviations: AT-MSC, adipose-tissue mesenchymal stem cell; Cas-3, caspase-3; DAPI, 4,6-diamidino-2-phenylindole; DTZ, dithizone; ES cell, embryonic stem cell; FITC, fluorescein isothiocyanate; IEQ, islet equivalent; INS, insulin; iPS cell, induced pluripotent stem cell; Luc-Tg rat, luciferase-transgenic rat; PCNA, proliferating cell nuclear antigen; PDX1, pancreatic and duodenal homeobox protein-1; UW, University of Wisconsin; ZO1, zona occludens 1.
  • 大柿 景子, 大友 慎也, 牛島 健太郎, 眞田 幸弘, 大西 康晴, 岡田 憲樹, 平田 雄大, 佐久間 康成, 今井 靖
    日本臨床薬理学会学術総会抄録集 43回 1-6 2022年12月  
  • 松本 志郎, 川平 洋, 千葉 蒔七, 窪木 大悟, 篠原 翔一, 太田 学, 佐久間 康成, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本内視鏡外科学会雑誌 27(7) 1416-1416 2022年12月  
  • 堀内 俊男, 眞田 幸弘, 大豆生田 尚彦, 平田 雄大, 岡田 憲樹, 大西 康晴, 佐久間 康成, 山口 博紀, 佐田 尚宏
    日本小児外科学会雑誌 58(7) 1011-1016 2022年12月  
  • 平田 雄大, 眞田 幸弘, 大西 康晴, 岡田 憲樹, 堀内 俊男, 佐久間 康成
    肝臓 63(12) 538-540 2022年12月  
    対象は肝移植後外来フォロー中の2021年12月~2022年5月にCOVID-19陽性となった小児18例(男児8例、女児10例)で肝移植時年齢中央値0歳、感染時年齢中央値12歳、肝移植後感染時期は移植後131ヵ月であった。臨床症状は咳嗽12例(66.7%)、発熱10例(55.6%)、鼻汁8例(44.4%)、咽頭痛6例(33.3%)の順であり、重症度は全例軽症であった。COVID-19の移植医療における基本指針の第5版のガイドラインに基づき、ミコフェノール酸モフェチル(MMF)内服中の5例中2例にMMFを半量に減量する指示を行ったが、抗ウイルス薬を投与した症例はなく、全例後遺症なく治癒した。
  • Yukihiro Sanada, Yasunaru Sakuma, Yasuharu Onishi, Noriki Okada, Yuta Hirata, Toshio Horiuchi, Takahiko Omameuda, Alan Kawarai Lefor, Naohiro Sata
    Pediatric transplantation 26(8) e14402 2022年12月  
    BACKGROUND: Repeat liver transplantation (LT) for patients with the liver graft failure who underwent metallic stent placement in the previous graft hepatic vein (HV) for HV complications can be very difficult. We retrospectively reviewed the safer surgical procedures during repeat LT for patients with a metallic stent in the graft HV. CASE REPORTS: Patient 1 with biliary atresia who was treated with metallic stent placement for HV stenosis underwent a third LT form a deceased donor at the age 17 years. Patient 2 with ornithine transcarbamylase deficiency who was treated with metallic stent placement for refractory HV stenosis underwent a second LT form a deceased donor at age 9 years. In both patients, transection of the previous graft HV through an intraabdominal approach was difficult during repeat LT, and a supradiaphragmatic inferior vena cava (IVC) approach was introduced. Using a midline incision of the diaphragm, the pericardium was incised and the supradiaphragmatic IVC was encircled. After clamping the supradiaphragmatic IVC, graft hepatectomy was performed. The metallic stent was successfully removed breaking, and HV reconstruction was performed on the suprahepatic IVC. Both patients did well without serious HV complications after repeat LT. CONCLUSIONS: The surgical technique for the supradiaphragmatic IVC approach is useful to decrease the risk of fatal operative complications during repeat LT for patients with a metallic stent in the graft HV.
  • 森嶋 計, 笹沼 英紀, 下平 健太郎, 田口 昌延, 遠藤 和洋, 佐久間 康成, 北山 丈二, 佐田 尚宏
    日本内視鏡外科学会雑誌 27(7) 563-563 2022年12月  
  • 下平 健太郎, 笹沼 英紀, 田口 昌延, 森嶋 計, 金丸 理人, 佐久間 康成, 細谷 好則, 堀江 久永, 北山 丈二, 佐田 尚宏
    日本内視鏡外科学会雑誌 27(7) 1693-1693 2022年12月  
  • Daisuke Matsubara, Taichiro Yoshimoto, Ninad Akolekar, Takashi totsuka, Yusuke, Amano, Atsushi Kihara, Tamaki Miura, Yuriko Isagawa, Yuji Sakuma, Shumpei, Ishikawa, Tetsuo Ushiku, Masashi Fukayama, Toshiro Niki
    Cancer Science 2022年12月  査読有り
  • Atsushi Miki, Yasunaru Sakuma, Hideyuki Ohzawa, Akira Saito, Yoshiyuki Meguro, Jun Watanabe, Kazue Morishima, Kazuhiro Endo, Hideki Sasanuma, Atsushi Shimizu, Alan Kawarai Lefor, Yoshikazu Yasuda, Naohiro Sata
    World Journal of Gastroenterology 28(38) 5614-5625 2022年10月14日  
  • 山田 百合子, 谷口 理丈, 佐田友 藍, 田原 真紀子, 田中 保平, 太田 学, 本間 祐子, 太白 健一, 鯉沼 広治, 堀江 久永, 山口 博紀, 佐久間 康成, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 83(増刊) S351-S351 2022年10月  
  • 大柿 景子, 大友 慎也, 眞田 幸弘, 大西 康晴, 岡田 憲樹, 平田 雄大, 牛島 健太郎, 佐久間 康成, 佐田 尚宏, 須藤 俊明, 今井 靖
    日本病院薬剤師会雑誌 58(9) 1024-1028 2022年9月  
  • 松浦 博和, 森嶋 計, 下平 健太郎, 齋藤 晶, 青木 裕一, 目黒 由行, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 83(9) 1659-1659 2022年9月  
  • 眞田 幸弘, 佐久間 康成, 大西 康晴, 岡田 憲樹, 平田 雄大, 堀内 俊男, 大豆生田 尚彦, 横山 健介, 矢野 智則, 山本 博徳, 佐田 尚宏
    胆と膵 43(7) 685-690 2022年7月  
  • Atsushi Miki, Yoko Matsuda, Junko Aida, Jun Watanabe, Yukihiro Sanada, Yasunaru Sakuma, Alan K. Lefor, Noriyoshi Fukushima, Naohiro Sata, Tomio Arai, Kaiyo Takubo, Toshiyuki Ishiwata
    Pancreas 51(6) 678-683 2022年7月  
  • Jun Watanabe, Atsushi Miki, Yasunaru Sakuma, Kentaro Shimodaira, Yuichi Aoki, Yoshiyuki Meguro, Kazue Morishima, Kazuhiro Endo, Hideki Sasanuma, Alan Kawarai Lefor, Takumi Teratani, Noriyoshi Fukushima, Joji Kitayama, Naohiro Sata
    Cancers 14(9) 2022年4月28日  
    BACKGROUND: Osteopenia is defined as low bone mineral density (BMD) and has been shown to be associated with outcomes of patients with various cancers. The association between osteopenia and perihilar cholangiocarcinoma is unknown. The aim of this study was to evaluate osteopenia as a prognostic factor in patients with perihilar cholangiocarcinoma. METHODS: A total of 58 patients who underwent surgery for perihilar cholangiocarcinoma were retrospectively analyzed. The BMD at the 11th thoracic vertebra was measured using computed tomography scan within one month of surgery. Patients with a BMD < 160 HU were considered to have osteopenia and b BMD ≥ 160 did not have osteopenia. The log-rank test was performed for survival using the Kaplan-Meier method. After adjusting for confounding factors, overall survival was assessed by Cox's proportional-hazards model. RESULTS: The osteopenia group had 27 (47%) more females than the non-osteopenia group (p = 0.036). Median survival in the osteopenia group was 37 months and in the non-osteopenia group was 61 months (p = 0.034). In multivariable analysis, osteopenia was a significant independent risk factor associated with overall survival in patients with perihilar cholangiocarcinoma (hazard ratio 3.54, 95% confidence interval 1.09-11.54, p = 0.036), along with primary tumor stage. CONCLUSIONS: Osteopenia is associated with significantly shorter survival in patients with perihilar cholangiocarcinoma.
  • 川平 洋, 鈴木 義彦, 前田 佳孝, 兼田 裕司, 太田 学, 松本 志郎, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 122回 DP-6 2022年4月  
  • 太田 学, 川平 洋, 千葉 蒔七, 篠原 翔一, 窪木 大悟, 松本 志郎, 兼田 裕司, 塩澤 幹雄, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 122回 DP-6 2022年4月  
  • 太白 健一, 遠藤 和洋, 森嶋 計, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, Alan Lefor, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 122回 DP-7 2022年4月  
  • 小林 冬美, 金丸 理人, 金子 勇貴, 高橋 和也, 高木 徹, 倉科 憲太郎, 斎藤 心, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本胃癌学会総会記事 94回 490-490 2022年3月  
  • 松浦 博和, 金丸 理人, 金子 勇貴, 高橋 和也, 高木 徹, 倉科 憲太郎, 齋藤 心, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本胃癌学会総会記事 94回 416-416 2022年3月  
  • Yukihiro Sanada, Yasunaru Sakuma, Yasuharu Onishi, Noriki Okada, Yuta Hirata, Toshio Horiuchi, Takahiko Omameuda, Koshi Matsumoto, Alan Kawarai Lefor, Naohiro Sata
    Transplant immunology 71 101557-101557 2022年2月23日  
    BACKGROUND: Sinusoidal obstruction syndrome (SOS) after liver transplantation (LT) is a rare and potentially lethal complication. We retrospectively reviewed the outcomes of patients with post-transplant SOS. METHODS: Between May 2001 and December 2019, of 332 patients who underwent LT, 5 (1.5%) developed SOS. The median age at LT was 1.7 years (range 0.1-66.5). SOS was histopathologically diagnosed and classified as early-onset (<1 month) or late-onset. RESULTS: The median time to diagnosis of SOS was one month after LT. All patients developed acute cellular rejection before SOS, and the cause of SOS was acute cellular rejection in four patients and unknown in one. The treatment of SOS included conversion to tacrolimus from cyclosporine, intrahepatic hepatic vein stent placement, strengthening of immunosuppression, and plasma exchange. The 5-year graft survival rates in patients with and without SOS were 53.0% and 92.5%, respectively (p < 0.001). Of three patients with early-onset SOS, two patients improved and are doing well, and one patient died of graft failure four months after LT. CONCLUSIONS: The cause and treatment of post-transplant SOS are not yet defined. The poor outcomes in patients with early-onset SOS may be improved by strengthening of immunosuppression. Patients with late-onset SOS are ultimately treated by repeat LT.
  • Hiroshi Maeda, Kouichi Miura, Naoki Morimoto, Shunji Watanabe, Mamiko Tsukui, Yoshinari Takaoka, Hiroaki Nomoto, Rie Goka, Naoto Sato, Kazue Morishima, Yasunaru Sakuma, Naohiro Sata, Noriyoshi Fukushima, Norio Isoda, Hironori Yamamoto
    Cancers 14(3) 2022年1月31日  
    BACKGROUND: Conventional therapies, including chemoembolization and radiation therapy, have been expected to prolong the prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases, which remains poor. However, little information is available on the efficacy of conventional therapies for such patients under tyrosine kinase inhibitor (TKI) treatment. METHODS: We retrospectively investigated 127 HCC patients with extrahepatic metastases, who were divided into the non-TKI (conventional therapies) and TKI groups and further subdivided into the TKI alone and TKI plus conventional therapies groups. Conventional therapies included transcatheter arterial chemoembolization, cisplatin-based chemotherapy, radiation, surgery, and UFT, an oral chemotherapeutic agent. RESULTS: The median of the overall survival (OS) of the 127 patients with extrahepatic metastases was 7.0 months. Meanwhile, the median OS of the TKI and non-TKI groups was 12.1 and 4.1 months, respectively. Imitating TKI after diagnosing metastases promoted a favorable increase in OS. Among the TKI group, the median OS in the TKI alone group was 8.9 months. TKI plus conventional therapies promoted no improvement in OS after adjusting for the patients' background data. CONCLUSION: TKI promoted a better OS in HCC patients with extrahepatic metastases compared to conventional therapies. However, TKI plus conventional therapies promoted no improvement in the prognosis of such patients.

MISC

 137

書籍等出版物

 2

共同研究・競争的資金等の研究課題

 15